Repurposing JAK inhibitors to treat type 1 diabetes

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1145507

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Type 1 diabetes occurs when the immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. Beta cells have to respond to molecules called cytokines for T cells to be able to kill them. We have identified a drug, called a JAK inhibitor, which will block the effects of cytokines on beta cells and cells of the immune system. The goal of this work is perform pre-clinical assessment of this drug, and test whether it has effects on type 1 diabetes in people.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2021

Funding Scheme: Project Grants

Funding Amount: $947,874.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Endocrinology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

JAK/STAT pathway | autoimmunity | clinical studies | cytokines | type 1 diabetes mellitus (insulin-dependent diabetes mellitus)

Related Links